# A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

> **NCT05055323** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 20 (actual)

## Conditions studied

- Resectable Pancreatic Ductal Adenocarcinoma
- Stage 0 Pancreatic Cancer AJCC v8
- Stage I Pancreatic Cancer AJCC v8
- Stage IA Pancreatic Cancer AJCC v8
- Stage IB Pancreatic Cancer AJCC v8
- Stage II Pancreatic Cancer AJCC v8
- Stage IIA Pancreatic Cancer AJCC v8
- Stage IIB Pancreatic Cancer AJCC v8

## Interventions

- **DRUG:** Pyrvinium Pamoate

## Key facts

- **NCT ID:** NCT05055323
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-29
- **Primary completion:** 2024-08-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055323, "A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05055323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*